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1. InTrODuCTIOn
COPD is characterized by the progressive worsening
and irreversible limitation of the expiratory airflow,
primarily as a result of the chronic inflammation of the
distal branches of the tracheobronchial tree. It is clas-
sified, according to GOLD (The Global Initiative for
Chronic Obstructive Lung Disease) in four stages,
based on spirometric results pre- and post- bronchodi-
lation (Table 1). Its prevalence is rather underestimated,
while this nosologic entity is directly associated with
high morbidity and mortality. COPD is estimated to
be the third leading cause of deaths worldwide, con-
stituting a significant financial burden to the modern,
long-suffering from crisis economy. COPD exacerba-
tions, mainly reported in winter, are directly correlated
with adverse prognosis1. 
Modern therapeutic strategy of COPD involves two
classes of drugs: bronchodilators and anti-inflammatory
drugs (Table 2). New pharmaceutical agents are under
development, while roflumilast, a selective inhibitor
of the enzyme phosphodiesterase 4(PDE4) – first pre-
pared in 1993- has already been approved by the FDA
for its introduction in clinical practice, having however
indication for a specific phenotype of COPD2. Practi-
cally, roflumilast is the first non-steroidal anti-inflam-
matory agent introduced in clinical practice as a sec-
ond-line drug for the therapeutic management of pa-
tients suffering from COPD3.
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Table 1. GOLD COPD classification 
Stage I (Mild) Stage II(Moderate) Stage III(Severe) Stage IV(Very severe)
FEV1/FVC<0.7 FEV1/FVC<0.7 FEV1/FVC<0.7 FEV1/FVC<0.7
FEV1≥ 80% predicted FEV1 50-79% predicted FEV1 30-49% predicted FEV1 <30%predicted, or 
<50% predicted with chronic
respiratory failure present 
Its inhibitory effect on PDE4 induces the intracellular
accumulation of cyclic adenosine monophosphate
(cAMP). Subsequently, protein kinase A (PKA) is ac-
tivated. In a randomized clinical study conducted by
Hohfeld et al.4 it was found that roflumilast blocks the
recruitment of neutrophils and eosinophils. Roflumilast
also inhibits the secretion of cytokines (especially T-
NF-α), but it lacks bronchodilator properties. The exact
mechanism of its action is still under investigation. It
is administered at a daily dose of 500 μg per os and it
is rapidly metabolized in roflumilast-N-oxide (>90%
of total activity) by the enzymes of cytochrome P450,
especially 3A4 and 1A2. Thus, the co-administration
with drugs that induce cytochro me’s enzymes is con-
traindicated (for example: rifampicin 600 mg, fluvox-
amine 50 mg). After oral administration, roflumilast
is quickly and completely absorbed (maximum plasma
concentration in one hour), while its bioavailability is
estimated at almost 80%5-7. 
After systematically reviewing 11 recent relevant
publications (table 3), we aim through this review article
at presenting the early data from the use of roflumilast
in clinical practice and the nomination of future
prospects for its position in modern therapeutic patterns
in COPD, as well. 
2. ExPErIMEnTAl DATA
Experimental studies have shown in vitro that roflu-
milast and its main metabolite, roflumilast N-oxide re-
duce LPS (lipopolysaccharide) –endotoxin induced se-
cretion of TNF-and chemokines that contribute to the
recruitment of monocytes and T-lymphocytes, such as
CCL2, CCL3, CCL4, CXCL9, and CXCL108. Nonethe-
less, equivalent suppressive effect on the secretion of
chemokines that mobilize neutrophils, such as CXCL1,
CXCL5 and CXCL8, was not proved.  Therefore, rof-
lumilast exerts a suppressant effect on two of the three
major cellular populations, which are involved in the
pathophysiology of COPD9. 
At a molecular level, roflumilast induces: a) in-
creased expression of HDAC2 (histone deacetylase 2)
and MKP1 (mitogen-activated protein kinase phos-
phatase 1), b) inhibition of kinases p38, JUN, ERK1 /
2 and finally c) expression of NF-κΒ (nuclear factor
kappa-light-chain-e nhancer of activated B cells), mod-
ifying the subject oxidative stress.
Based on this effect of roflumilast, it is possible that,
if it is added to a therapeutic pattern including inhaled
corticosteroids (ICs), it is feasible to reverse the resis-
tance to them, and thus optimize the anti-inflammatory
result10-12.
Additionally, there is experimental evidence that
roflumilast exerts a stimulatory effect on VEGF (Vas-
cular Endothelial Growth Factor), which contributes
to the growth and survival of endothelial cells, as well
as to the maintenance of the vascular tone in the pul-
monary microcirculation13. 
3. ClInICAl DATA
Based on clinical trials and meta-analyses conducted
until now, there is consensus as to the phenotype of
those patients with COPD, who would benefit from
daily administration of roflumilast, as a second-line
drug: COPD stage III-IV, with chronic bronchitis and
frequent exacerbations (some authors suggest >2 ex-
acerbations/year and others >4)14,15. It should be noted,
that roflumilast induced decrease in the exacerbation
rate is underestimated, when it is added on a regimen
consisting of first-line drugs16.
Martinez et al. conducted a one year double-blind
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Table 2. Drugs currently used in COPD 
bronchodilators Anti-inflammatory
1. Short acting
• b-agonists (SABAs): salbutamol, Corticosteroids
albuterol, pirbuterol
• anticholinergic: ipratropium • Inhaled corticosteroids (fluticasone, budesonide):
in stable COPD and in acute exacerbations
2. Long acting
• b- agonists(LABAs): salmeterol, formoterol • Systemic corticosteroids (prednisolone, 
• anticholinergic: tiotropium methylprednisolone): in acute exacerbations
• methylxanthine(non selective PDE inhibitor):
theophylline 
multicenter study on 1945 selected patients. Nine hun-
dred and seventy-three of them were given roflumilast
(group A) and 972 received placebo (group B). It was
shown that in group A there was a reduction in yearly
exacerbations by almost 14%, compared to group B.
However, twice as many patients of group A, discon-
tinued treatment due to roflumilast’s side effects17.
Yan et al. after a meta-analysis of eleven different
clinical trials conducted on 9675 patients, selected with
common criteria, concluded that roflumilast: a) reduces
the mean rate of annual exacerbations (p<0.00001),
b) improves FEV1 (p<0.00001) and c) does not affect
the quality of life and the mortality rate of these patients
(p=0.49 and 0.56 respectively)18. Oba et al. conducted
a respective meta-analysis of eight clinical trials in a
total of 8698 patients with the typical phenotype and
reached similar conclusions19.
Wedzicha et al. substantiated that roflumilast re-
duces the number of exacerbations per year (p=0.0148)
and stabilizes the severity of the disease (p=0.0018)20.
Regarding to the spirometric profile of these patients,
Pinner et al. proved that roflumilast increases FEV1by
36-88 mL (comparison of patients with the same phe-
notype, half of whom received roflumilast and the other
half received placebo), noting however that a high per-
centage of these patients (9-16%) dropped out of ther-
apy with roflumilast within the first twelve weeks, due
to intolerable side effects. They also assess that roflu-
milast does not affect the quality of life of the patients
with the typical phenotype21.
After systematic evaluation and processing of 29
randomized, placebo-controlled clinical trials, conducted
on a total of 19111 patients, with COPD stage II-IV
and an average age of sixty four years old, Chong et al.
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Table 3. Summary of early clinical data about roflumilast’s effectiveness in COPD.
researchers results
Martinez et al.17 • 13.7% ↓ of exacerbations
• 2x patients treated with ro.(in comparison with those given placebo)
withdrew from therapy
Yan et al. 18 • ↓ mean exacerbation rate
↑ • ↑ FEV1
↑ • quality of life
Oba et al. 19 • ↓ mean exacerbation rate
↑ • ↑ FEV1
↑ • ↔ quality of life
• ↑ withdrawal from therapy due to side effects
Wedzicha et al. 20 • ↓ mean exacerbation rate
• Stabilizes clinical condition
Pinner et al.21 • ↑ FEV1
↑ • ↑ withdrawal from therapy due to side effects
Chong et al. 22 • ↑ FEV1
• ↓ mean exacerbation rate
• ↔ quality of life
• ↔ exercise tolerance
Lei Pan et al.23 • ↑ effectiveness of LAMAs
↑ • ↓ dyspnea
Mills et al.24 • ↑ effectiveness of LAMAs
Giembycz et al. 25 • Synergy with LABAs
• ↑ effectiveness of ICs
White et al. 26 • Controversy about its effect on MACEs
Lone et al.27
Abbreviations: FEV1, Forced Expiratory Volume in 1’’; LAMAs, long-acting muscarinic antagonists; LABAs, long-acting beta-2 agonists;
ICs, inhaled corticosteroids; MACEs, major adverse cardiovascular events
demonstrated the following regarding to roflumilast
and cilomilast: a) these agents increase FEV1 by 45.6
mL, b) they practically do not improve the quality of
life and the symptoms of these patients, c) they do not
alter patients’ exercise tolerance and d) they reduce
the mean exacerbation rate, preventing more aggressive
clinical intervention22.
Lei Pan et al. noted that roflumilast may have a fa-
vorable impact on dyspnea of patients with the above
phenotype, while it appears that co-administration of
roflumilast with anticholinergic agents is superior to
monotherapy23, reinforcing the aspect of Mills et al.,
expressed already in 2011, that roflumilast in co-ad-
ministration with LAMAs (Long Acting Muscarinic
Antagonists) provides clear benefits to patients with
chronic bronchitis and at least two exacerbations per
year24. 
Furthermore, roflumilast appears to act in synergy
with LABAs (Long Acting B2-Agonists), enhancing
that way the anti-inflammatory action of ICs (Inhaled
Corticosteroids)25. The potential cardiovascular benefit
of roflumilast in patients with COPD is under investi-
gation. There is evidence that it may contribute to the
decrease of the incidence of cerebrovascular events26,
but not that of the other major adverse cardiovascular
events (MACEs). Concerns about the higher incidence
of atrial fibrillation and atrial multifocal tachycardia
in COPD patients compared to those that received
placebo are on the rise as well27.
It seems that roflumilast is a reliable second-line a-
gent, possibly cost-effective28, as an add-on treatment
to the first-line bronchodilator and anti-inflammatory
drugs, for those COPD patients with well- defined phe-
notypic traits. 
A summary of the results of the above clinical studies
is shown in table 3. 
4. rESTrICTIOnS In ADMInISTrATIOn 
In all clinical trials and studies at present there is a con-
sensus regarding the indications of roflumilast’s ad-
ministration as well as its adverse effects , which con-
stitute a significant obstacle in its clinical use as an add-
on treatment. These side effects concern mainly the
gastrointestinal tract (nausea, vomiting, weight loss,
and diarrhea) and the Central Nervous System
(headache, insomnia, drowsiness). The average weight
loss amounts to 2.1 kilograms. Most of them occur with-
in the first 4-12 weeks after the start of administration,
leading to a high percentage of withdrawal from treat-
ment (9-16%)14,15,19.
We should especially mention the higher incidence
of atrial fibrillation and suicidal ideation in patients
who received roflumilast, compared to those that re-
ceived placebo (0.4 and 0.08% of patients with COPD
versus 0.2 and 0%, respectively19. Therefore, roflumilast
is contraindicated in patients suffering from depression
and having expressed suicidal thoughts at least once
before7. 
Absolutely contraindicated is the administration to
patients with chronic and advanced liver disease (Child-
Pugh Stages B-C), while no dose adjustment is required
in patients with renal impairment9,29. 
As it has been previously said, the co-administration
with drugs that induce P450 cytochrome’s enzymes is
also contraindicated30.
5. FuTurE PrOSPECTS-COnCluSIOnS 
It appears that the mechanism of nausea and emesis
is induced by the inhibition of the subtype D of PDE4
(PDE4D), while the anti-inflammatory effect is medi-
ated via the inhibition of the subtype B (PDE4B).
Hence, a more selective inhibitor of the second isoen-
zyme could possibly optimize the needed action, being
at the same time better tolerated7,10.
RPL554, a combined conjugated PDE3/PDE4 in-
hibitor is under investigation. It exerts both bronchodila-
tory (PDE3 inhibition) and anti-inflammatory (PDE4
inhibition) effects, while it can be administered via in-
halation, minimizing that way its systematic absorption,
and thus the occurrence of intolerable adverse events11-
13. There are also new signs, that such an agent tran-
scends a simple PDE4 inhibitor, because it is able to
enhance and prolong the effects of LABAs and ICs31.
In conclusion, roflumilast is a second-line agent,
indicated for patients suffering from COPD and with
a specific phenotype: chronic bronchitis and at least 2
exacerbations per year. This new drug needs further
evaluation, through experimental and clinical studies,
in order to better evaluate its clinical utility.
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Νεότερα δεδομένα για τη χρήση της ροφλουμιλάστης 
στη Χρόνια Αποφρακτική Πνευμονοπάθεια: άρθρο σύντομης ανασκόπησης
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Περίληψη: Η ροφλουμιλάστη αποτελεί  έναν νεότερο αντιφλεγμονώδη παράγοντα 2ης γραμμής για τη θεραπεία ασθενών
με συγκεκριμένο φαινότυπο Χρόνιας Αποφρακτικής Πνευμονοπάθειας. Στο παρόν άρθρο μετά από αναδίφηση της πλέον
πρόσφατης διεθνούς βιβλιογραφίας, επιχειρείται η παρουσίαση των έως τώρα πειραματικών αλλά και κλινικών αποτε-
λεσμάτων, όσον αφορά στα οφέλη που προκύπτουν από τη χρήση της, τους περιορισμούς της χορήγησης της, αλλά και τις
μελλοντικές προοπτικές για τη βελτιστοποίηση της δράσης  της.
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